• Kubilay Issever, Ahmed Cihad Genc, Deniz Cekic, Ilhan Yildirim, Ahmed Bilal Genc, and Selcuk Yaylaci.
• Department of Internal Medicine, Sakarya Toyotasa Emergency State Hospital, Sakarya, Turkey.
• J Coll Physicians Surg Pak. 2021 Jul 1; 31 (7): S99-S103.

ObjectiveTo analyse whether prealbumin could be a new biomarker for predicting mortality in severe COVID-19 patients.Study DesignAn observation study.Place And Duration Of StudyIntensive care units (ICU) of Sakarya University Training and Research Hospital, Sakarya, Turkey, from October 2020 to December 2020.MethodologyThe data of 149 patients, who were admitted to the ICU were collected and analysed retrospectively. Routine blood samples were collected from all patients at the time of admission to the ICU; and 102 patients with the mortal course and 47 patients with the non-mortal course were included in the study. The data obtained from these patients were analyzed in the biostatistics programme.  Results: The median age of all patients was 68 years; while 94 of them were males (63.1%) and 55 of them were females (36.9%). Median levels of potassium (K) (p=0.04), uric acid (p=0.001), C-reactive protein (CRP) (p=0.004), and procalcitonin (PCT) (p<0.001) were significantly higher and median level of prealbumin (p=0.002) was significantly lower in the deceased group. The cut-off level of prealbumin for mortality was found as 0.085 g/L (p=0.002). Further analysis revealed that the risk of mortality was found as 2.193 times more in patients with prealbumin levels of <0.085 g/L (Odds Ratio (OR): 2.193, 95% CI: 1.084-4.434).ConclusionAs a result of this study, it was found that patients with lower levels of prealbumin at the time of admission to the ICU have a higher risk for mortality. It was showed that prealbumin can be a useful biomarker for predicting mortality in patients with severe COVID-19. Key Words: Prealbumin, COVID-19, Mortality, Prognostic biomarkers, Severe disease.

22 keywords...

hide…